NEWS
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
Hoth Therapeutics (NASDAQ: HOTH) has entered a Master Services Agreement with Aronnax Inc. for its HT-KIT cancer therapeutic.
Hoth Therapeutics (NASDAQ: HOTH) has entered a Master Services Agreement with Aronnax Inc. for its HT-KIT cancer therapeutic.
Aronnax will oversee ITR Laboratories in conducting intravenous injection studies to determine the Maximum-Tolerated Dose (MTD) and perform a Dose Range-Finding Phasefor HT-KIT.
HT-KIT, an antisense oligonucleotide targeting the proto-oncogene cKIT, has shown promising results in killing human mast cells and reducing KIT expression in GIST and AML cells. It has received Orphan Drug Designation from the FDA for treating mast cell-derived cancers and anaphylaxis.
This study aims to provide Hoth with key metrics for formulating its proposed clinical trial, advancing HT-KIT towards an IND-enabling study.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1688Followers
93Following
13KVisitors
Follow